Actinium pharmaceuticals continues to promote results from their phase 3 clinical trial regarding the iomab-b drug. While this is positive news, the fact that there are people currently suffering with refractory aml who can not get access to this treatment continues to be frustrating beyond belief. The sooner this gets the go ahead from the FDA for an early access program the more lives can be impacted and saved.

The understanding as I currently know it is that Actinium is filing the necessary paperwork for early access programs for the second half of 2023. Obviously, this is encouraging, but a disease like AML is unpredictable and dangerous. For people currently suffering, the wait should not be at the mercy of the federal government. The FDA should act on treatments like this sooner than later. With your help, I know we can push this further onto their radar, but we need more support.

Time is of the essence and with your support we have pushed this petition onto the radar of Actinium Pharmaceuticals and they are pushing ahead to get the early access program approved! We need the FDA to expedite the process as well! When the time came my Dad responded on 9/11, then the government lied about the quality of the air and now he has aml. The 3,000 lives lost that day was devastating enough, the tens of thousands of first respondeds lost since is increasingly overwhelming. Treatments like this can help turn that tide. 

With your support, I know we can get the FDA to recognize this treatment and expedite the approval process and help save the lives of those suffering with refractory aml and other refractory illnesses. 

Thank you!